A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
August 02, 2021 at 21:59 PM EDT
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant upside for the company stock.
